“…In a double-blind human study, a 5-wk supplementation with n-3 PUFAs significantly decreased exhaled NO from young (22-29-yr-old) asthma patients challenged with low-dose dust mite allergen, reduced the blood eosinophil count and inhibited the antigeninduced cysLT production by isolated leukocytes from these patients [153]. These results indicate that the effect of n-3 PUFAs on allergic responses might be dependent on how n-3 PUFAs are provided to the patients in terms of the PUFA dose, the Inhibition [69] IL-5 Human, mouse [70,71] Stimulates eosinophil differentiation and function [72] Inhibition [69] IL-6 Human, mouse [61,73] Induces B cell and cytotoxic T cell differentiation, promotes macrophage activation [74] Unknown IL-8 Human, mouse [57,75] Recruits monocytes/macrophages, promotes angiogenesis [76] Unknown IL-10 Human, mouse [71,77] Inhibits macrophage activation, promotes regulatory T cell function [78] Unknown IL-13 Human, mouse [71,79] Promotes eosinophil recruitment and airway smooth muscle cell contractility [80,81] Inhibition [69] IL-17 Human [82] Promotes tissue remodeling and production of proinflammatory cytokines [83] Unknown IL-33 Mouse [84] Promotes regulatory T cell function and Th2 response [85] Unknown (continued on next page) specific type of n-3 PUFAs, the age of the subjects, and the severity of their disease.…”